Copyright
©The Author(s) 2019.
World J Gastroenterol. Sep 14, 2019; 25(34): 5049-5068
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5049
Published online Sep 14, 2019. doi: 10.3748/wjg.v25.i34.5049
Target antigen of auto-anti-bodies | Authors, year | ESCC cases, n | Stage, n | Con-trols, n | P value | Sensiti-vity, all stages/ early stage | Specifi-city, all stages/ early stage | AUC, all stages/ early stage | Method | ||||
0/I | II | III | IV | Tx | |||||||||
Survivin | Xiu et al[57], 2018 | 159 | - | - | - | - | 159 | 362 | 0.524 | 14.5%/- | 90.0%/- | 0.327/- | ELISA |
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 12.1%/- | 99.6%/- | 99.6/- | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | 0.06 | 9.0%/- | 96.0%/- | - | ELISA | |
Meglior-ino et al[59], 2005 | 77 | - | - | - | - | 77 | 82 | < 0.05 | 10.4%/- | 97.6%/- | - | ELISA | |
TOPO48 | Zhang et al[60], 2018 | 112 | 29 | 28 | 28 | 27 | - | 112 healthy volunte-ers and 75 esopha-geal benign tumor patients | 0.001 | 49.1%/ 61.4% | 100%/ 100% | -/0.860 | ELISA |
L1CAM | Xu et al[61], 2017 | 191 (Cohort 1) | 10 | 104 | 77 | - | - | 94 (Cohort 1) | 0.005 | 26.2%/ 25.2% | 90.4%/ 90.4% | 0.603/ 0.611 | ELISA |
47 (Cohort 2) | 5 | 18 | 24 | - | - | 47 (Cohort 2) | 0.032 | 27.7%/ 33.3% | 91.5%/ 91.5% | 0.628/ 0.636 | ELISA | ||
Ezrin | Li et al[62], 2017 | 149 | 4/14 | 57 | 71 | 3 | 149 | 98 | < 0.0001 | 27.5%/ 27.8% | 95.9%/ 95.9% | - | ELISA |
STIP1 | Xu et al[63], 2017 | 148 (Train-ing) | 3/17 | 48 | 76 | 4 | 148 | 111 (Train-ing) | < 0.001 | 41.9%/ 35.7% | 90.1%/ 90.1% | 0.682/ 0.684 | ELISA |
60 (Valida-tion) | 1/8 | 20 | 30 | 1 | 60 | 40 (Valida-tion) | < 0.001 | 40.0%/ 38.5% | 92.5%/ 92.5% | 0.710/ 0.756 | ELISA | ||
Fascin | Chen et al[64], 2017 | 149 | 4/14 | 57 | 71 | 3 | 149 | 98 | < 0.001 | 24.8%/ 20.6% | 99.0%/ 99.0% | 0.636/ 0.632 | ELISA |
DKK-1 | Peng et al[65], 2016 | 185 (Train-ing) | 4/23 | 69 | 85 | 4 | 185 | 97 (Train-ing) | < 0.0001 | 33.5%/ 34.6% | 91.8%/ 91.8% | 0.643/ 0.640 | ELISA |
104 (Valida-tion) | 1/12 | 35 | 53 | 3 | 104 | 53 (Valida-tion) | < 0.0001 | 33.7%/ 26.9% | 92.5%/ 92.5% | 0.629/ 0.603 | ELISA | ||
P16 | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 29.3%/- | 81.8%/- | 0.60/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.01 | - | - | - | ELISA | ||
Jin et al[66], 2015 | 88 | 24 | 42 | 15 | 2 | 5 | 208 | 0.0052 | 5.7%/- | 99.1%/- | - | ELISA | |
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 18.4%/- | 98.8%/- | 0.6/- | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | 0.004 | 11.0%/- | 97.0%/- | - | ELISA | |
Looi et al[67], 2006 | 71 | - | - | - | - | - | 82 | < 0.05 | 14.1%/- | 98.8%/- | - | ELISA | |
p53 | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 55.9%/- | 89.5%/- | 0.784/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.001 | -/- | -/- | -/- | ELISA | ||
Xu et al[43], 2014 | 388 (Test) | 2/29 | 96 | 229 | 27 | 5 | 125 (Test) | < 0.0001 | 30.0%/- | 98.0%/- | - | ELISA | |
237 (Valida-tion) | 2/31 | 114 | 90 | - | - | 134 (Valida-tion) | < 0.0001 | 29.0%/- | 97.0%/- | - | ELISA | ||
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 21.8%/- | 96.3%/- | 0.6/- | ELISA | |
Chai et al[68], 2014 | 157 | - | - | - | - | 157 | 85 | < 0.01 | 22.9%/- | 100%/- | - | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | < 0.001 | 22.0%/- | 98.0%/- | - | ELISA | |
Cai et al[69], 2008 | 46 | 10 | 17 | 14 | 5 | - | 30 | < 0.0001 | 39.1%/ 22.2% | 100%/ 100% | - | ELISA | |
Looi et al[67], 2006 | 71 | - | - | - | - | 71 | 82 | < 0.05 | 7%/- | 98.8%/- | - | ELISA | |
Müller et al[70], 2006 | 50 | - | - | - | - | 50 | 436 | < 0.05 | 20.0%/- | 100%/- | - | Western blot | |
Meglior-ino et al[59], 2005 | 77 | - | - | - | - | 77 | 82 | < 0.01 | 14.3%/- | 97.6%/- | - | ELISA | |
Shimada et al[71], 2003 | 301 | - | - | - | - | 301 | 205 | < 0.05 | 30.0%/- | 95.5%/- | - | ELISA | |
Shimada et al[72], 2002 | 105 | 50 | 24 | 21 | 10 | - | 153 | < 0.001 | 26.7%/ 20.0% | 95.5%/ 95.5% | - | ELISA | |
Ralhan et al[73], 2000 | 60 | - | - | - | - | 60 | 50 | < 0.05 | 60.0%/- | 92.0%/- | - | ELISA | |
Shimada et al[74], 2000 | 35 | - | - | - | - | 35 | 69 | < 0.0001 | 40.0%/- | 100.0%/- | - | ELISA | |
Hagi-wara et al[75], 2000 | 46 | 6 | 15 | 24 | 2 | - | 13 | < 0.05 | 28.0%/ 28.6% | 100%/ 100% | - | ELISA | |
Shimada et al[76], 1998 | 57 | 6/9 | 9 | 11 | 11 | 1 | 208 | < 0.05 | 58.0%/- | 99.0%/- | - | ELISA | |
Sobti et al[77], 1998 | 20 | - | - | - | - | 20 | 20 | 0.0202 | 30.0%/- | 100%/- | - | ELISA | |
Cawley et al[78], 1988 | 23 | - | - | - | - | 23 | 19 | 0.0372 | 34.8%/- | 94.7%/- | - | ELISA | |
NY-ESO-1 | Xu et al[43], 2014 | 388 (Test) | 2/29 | 96 | 229 | 27 | 5 | 125 (Test) | < 0.0001 | 26.0%/- | 100%/- | - | ELISA |
237 (Valida-tion) | 2/31 | 114 | 90 | - | - | 134 (Valida-tion) | < 0.0001 | 24.0%/- | 99.0%/- | - | ELISA | ||
Oshima et al[79], 2016 | 172 | - | - | - | - | 172 | 74 | < 0.001 | 32.0%/ 16.0% | 100%/ 100% | - | ELISA | |
Fujita et al[80], 2004 | 51 | - | - | - | - | 51 | 29 | 0.532 | 3.9%/- | 100%/- | - | ELISA | |
P90 | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 31.5%/- | 84.9%/- | 0.617/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.001 | - | - | - | ELISA | ||
Mmp-7 | Xu et al[43], 2014 | 388 (Test) | 2/29 | 96 | 229 | 27 | 5 | 125 (Test) | < 0.001 | 9.0%/- | 100%/- | - | ELISA |
237 (Valida-tion) | 2/31 | 114 | 90 | - | - | 134 (Valida-tion) | < 0.001 | 10.0%/- | 100%/- | - | ELISA | ||
Zhou et al[81], 2011 | 50 | - | - | - | - | 50 | 58 | < 0.001 | 78.0% | 81.0% | 0.87/- | ELISA | |
Hsp70 | Xu et al[43], 2014 | 388 (Test) | 2/29 | 96 | 229 | 27 | 5 | 125 (Test) | < 0.001 | 11.0%/- | 99.0%/- | - | ELISA |
237 (Valida-tion) | 2/31 | 114 | 90 | - | - | 134 (Valida-tion) | < 0.01 | 8.0%/- | 99.0%/- | - | ELISA | ||
Zhang et al[82], 2011 | 69 | - | - | - | - | 69 | 76 | > 0.01 | 39.1%/- | 92.3%/- | - | ELISA | |
Fujita et al[40], 2008 | 16 | 2 | 7 | 4 | 3 | - | 13 | < 0.001 | 93.7%/- | 100%/- | - | ELISA | |
PRDX 6 | Xu et al[43], 2014 | 388 (Test) | 2/29 | 96 | 229 | 27 | 5 | 125 (Test) | < 0.001 | 11.0%/- | 100%/- | - | ELISA |
237 (Valida-tion) | 2/31 | 114 | 90 | - | - | 134 (Valida-tion) | < 0.001 | 10.0%/- | 100%/- | - | ELISA | ||
Fujita et al[83], 2006 | 30 | 7 | 8 | 11 | 4 | - | 30 | < 0.05 | 50.0%/ 53.5% | 93.4%/ 93.4% | - | Western blot | |
Bmi-1 | Xu et al[43], 2014 | 388 (Test) | 2/29 | 96 | 229 | 27 | 5 | 125 (Test) | < 0.01 | 11.0%/- | 98.0%/- | - | ELISA |
237 (Valida-tion) | 2/31 | 114 | 90 | - | - | 134 (Valida-tion) | < 0.01 | 8.0%/- | 100%/- | - | ELISA | ||
Liu et al[84], 2010 | 159 | 6 | 72 | 69 | 12 | - | 102 | < 0.001 | 39.0%/- | 100%/- | - | ELISA | |
Imp1 | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 26.9%/- | 81.2%/- | 0.576/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.01 | - | - | - | ELISA | ||
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 16.1%/- | 98.3%/- | 0.6/- | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | < 0.001 | 14.0%/- | 99.0%/- | - | ELISA | |
Cyclin B1 | Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 16.1%/- | 97.9%/- | 0.6/- | ELISA |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | 0.02 | 10.0%/- | 97.0%/- | - | ELISA | |
C-Myc | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 49.1%/- | 81.5%/- | 0.699/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.001 | - | - | - | ELISA | ||
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 15.5%/- | 98.8%/- | 0.6/- | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | < 0.001 | 18.0%/- | 96.0%/- | - | ELISA | |
Looi et al[67], 2006 | 71 | - | - | - | - | - | 82 | < 0.05 | 7%/- | 100%/- | - | ELISA | |
Meglio-rino et al[59], 2005 | 77 | - | - | - | - | 77 | 82 | < 0.01 | 11.7%/- | 100%/- | - | ELISA | |
RalA | Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 15.5%/- | 96.7%/- | 0.6/- | ELISA |
P62 | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 29.3%/- | 81.8%/- | 0.60/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.001 | - | - | - | ELISA | ||
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 12.1%/- | 95.9%/- | 0.5/- | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | 0.001 | 13.0%/- | 98.0%/- | - | ELISA | |
Koc | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 35.8%/- | 82.1%/- | 0.63/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.05 | - | - | - | ELISA | ||
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 11.5%/- | 97.9%/- | 0.5/- | ELISA | |
Zhou et al[44], 2014 | 88 | - | - | - | - | 88 | 200 | 0.05 | 10.0%/- | 96.0%/- | - | ELISA | |
Cyclin D1 | Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 10.3%/- | 96.3%/- | 0.5/- | ELISA |
Cyclin E | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 26.5%/- | 83.0%/- | 0.581/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.05 | - | - | - | ELISA | ||
Qin et al[58], 2014 | 174 | 3/8 | 79 | 52 | 18 | - | 242 | < 0.05 | 10.3%/- | 99.2%/- | 0.5/- | ELISA | |
HCCR | Zhang et al[55], 2016 | 324 (Train-ing) | 5/13 | 130 | 50 | 39 | 87 | 324 (Train-ing) | < 0.001 | 34.6%/- | 80.0%/- | 0.596/- | ELISA |
186 (Valida-tion) | 1 | 29 | 14 | 46 | 96 | 186 (Valida-tion) | < 0.001 | - | - | - | ELISA | ||
GSTO1 | Li et al[85], 2014 | 67 | - | - | - | - | 67 | 90 | < 0.01 | 44.8%/- | 93.3%/- | - | ELISA |
MDM2 | Chai et al[68], 2014 | 157 | - | - | - | - | 157 | 85 | < 0.01 | 14.0%/- | 98.8%/- | - | ELISA |
HSP105 | Gao et al[51], 2014 | 46 | 7 | - | - | - | 39 | 40 | < 0.01 | 39.1%/ 42.9% | 95%/95% | 0.794/- | Western blot |
TIM | Gao et al[51], 2014 | 46 | 7 | - | - | - | 39 | 40 | < 0.01 | 34.8%/ 28.6% | 95%/95% | 0.786/- | Western blot |
Prdx1 | Ren et al[86], 2013 | 68 | - | - | - | - | 68 | 89 | < 0.01 | 13.2%/- | 100%/- | - | ELISA, Western blot |
FOXP3 | Ye et al[87], 2013 | 97 | 26 | 45 | 19 | 2 | 5 | 227 | < 0.0001 | 22.7%/- | 95.2%/- | 0.70/- | ELISA, |
CD25 | Guan et al[88], 2013 | 97 | 26 | 45 | 17 | 3 | 6 | 226 | < 0.001 | 37.2%/- | 90.0%/- | 0.69/- | ELISA |
ABCC3 (IgA) | Cheng et al[89], 2013 | 114 | - | - | - | - | - | 226 | < 0.001 | 13.2%/- | >95%/- | 0.65/- | ELISA |
LY6K | Zhang et al[90], 2012 | 62 | 13 | 27 | 22 | - | 58 | < 0.001 | 80.6%/ 73.2% | 78.7%/ 78.7% | 0.85/- | ELISA | |
HMGB1 | Zhang et al[82], 2011 | 69 | - | - | - | - | 69 | 76 | > 0.05 | 7.2%/- | 98.7%/- | - | ELISA |
ESCA-1 | Kagaya et al[91], 2011 | 146 | 32 | 29 | 42 | 43 | - | 118 | 0.0001 | 21.2%/- | 98.3%/- | - | ELISA |
ESCA-2 | Kagaya et al[91], 2011 | 72 | 37 | 35 | 72 | 98 | 0.0026 | 15.3%/ 8.1% | 99.0%/ 99.0% | - | ELISA | ||
ESCA-3 | Kagaya et al[91], 2011 | 68 | - | - | - | - | 68 | 74 | 0.0079 | 16.2%/- | 98.6%/- | - | ELISA |
CDC25B | Dong et al[92], 2010 | 134 | 80 | 54 | - | 134 | < 0.001 | 56.7%/- | 91.0% | 0.87/- | ELISA | ||
Liu et al[93], 2008 | 124 | - | - | - | - | 123 | 102 | < 0.05 | 36.3%/- | 100%/- | - | ELISA | |
GRP78 | Tsunemi et al[94], 2010 | 15 | - | - | - | - | 15 | 20 | < 0.05 | 26.7%/- | 100%/- | - | Western blot |
Makorin 1 | Shimada et al[95], 2009 | 73 | 1/13 | 21 | 27 | 11 | - | 43 | < 0.05 | 25.0%/ 22.9% | 100%/ 100% | - | Western blot |
CUEC-23 | Shimada et al[96], 2009 | 54 | 7 | 13 | 18 | 16 | - | 46 | < 0.05 | 26.0%/ 33.3% | 96.0%/- | - | Western blot |
Shimada et al[96], 2009 | 29 | 1 | 11 | 8 | 9 | - | 46 | 0.036 | 17.0%/- | 100%/- | - | ELISA | |
MMGL | Shimada et al[97], 2007 | 91 | 21 | 22 | 35 | 13 | - | 45 | < 0.05 | 47.0%/ 38.0% | 97.8%/ 97.8% | - | Western blot |
TRIM21 | Kubo-shima et al[98], 2006 | 91 | 39 | 52 | - | 42 | < 0.05 | 20.0%/ 13.0% | 100%/ 100% | - | Western blot | ||
Kubo-shima et al[98], 2006 | 54 | - | - | - | - | 54 | 42 | 0.013 | 15.0%/- | 98.0%/- | - | ELISA | |
SLC2A1 | Kubo-shima et al[99], 2006 | 57 | 19 | 6 | 13 | 19 | - | 31 | < 0.001 | 21.0%/ 22.0% | 100%/ 100% | - | ELISA |
SURF1 | Shimada et al[50], 2005 | 21 | - | 3 | 13 | 5 | - | 37 | 0.0003 | 48%/- | 95%/- | - | ELISA |
LOC 146223 | Shimada et al[50], 2005 | 21 | - | 3 | 13 | 5 | - | 37 | 0.0028 | 38%/- | 95%/- | - | ELISA |
HOOK2 | Shimada et al[50], 2005 | 21 | - | 3 | 13 | 5 | - | 37 | 0.0431 | 14%/- | 100%/- | - | ELISA |
AGENCOURT_7565913 | Shimada et al[50], 2005 | 21 | - | 3 | 13 | 5 | - | 37 | 0.0431 | 14%/- | 100%/- | - | ELISA |
TROP2 | Naka-shima et al[100], 2004 | 75 | 14 | 14 | 24 | 23 | - | 43 | < 0.05 | 31.0%/ 21.0% | 97.7%/ 97.7% | - | Western blot |
- Citation: Xu YW, Peng YH, Xu LY, Xie JJ, Li EM. Autoantibodies: Potential clinical applications in early detection of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma. World J Gastroenterol 2019; 25(34): 5049-5068
- URL: https://www.wjgnet.com/1007-9327/full/v25/i34/5049.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i34.5049